Avhandling för medicine doktorsexamen vid Sahlgrenska akademin, Institutionen för neurovetenskap och fysiologi, Sektionen för klinisk neurovetenskap
Opponent: docent Karin Gehring , Department of Cognitive Neuropsychology, Tilburg University, Tilberg, Nederländerna
Betygsnämnd: professor Andreas Fors (ordf.), professor Sussanne Börjeson(LiU) och docent Jane Skjoeth Rasmussen (Köpenhamn)
Disputationen hålls på engelska
Ordförande för disputationsakten: Professor Hans-Georg Kuhn
Slow-growing gliomas most often affect individuals in midlife. These tumors are incurable, but multimodal treatment has improved survival. Less is known about the consequences for patient functioning. This thesis investigates functional outcomes after treatment, focusing on work, mental health, cognition, and quality of life, to improve knowledge and identify risk factors.
The thesis is based on the following four studies:
Study I examines sick-leave patterns and return to work after first surgery using registry data. Patients with grade 2 gliomas and matched controls had similar sick-leave levels until the months before surgery, when levels increased in patients. After one year, 52% had returned to work, and after two years, 63%. Previous sick leave, older age, lower functional status, and oncological treatment delayed return to work at one year. Female sex, comorbidity, and biopsy were associated with lower return to work at two years.
Study II investigates dispensed antiepileptic, antidepressant, and sedative medications after first surgery in patients with grade 2 gliomas. Antidepressants were usually initiated months after surgery, whereas sedatives and antiepileptics increased around diagnosis. Prior use and related diagnoses were the main predictors. Antidepressant use increased in recent years, and female patients had higher use than both male patients and female controls.
Study III examines cognitive changes following treatment in a longitudinal multicenter study of patients with IDH-mutated gliomas. Cognitive impairments were common before treatment, and individual declines were mainly observed in executive function, memory, and language. Older age and chemoradiotherapy emerged as risk factors.
Study IV addresses how cognitive functioning relates to quality of life at different stages of the disease trajectory. Reduced global HRQoL was common. Learning and memory were most relevant at diagnosis, language and executive functions at one year, and executive function was strongly associated with HRQoL in the long-term group.
In conclusion, treatment is associated with functional consequences, and these findings underscore the need for systematic follow-up, early identification of patients at risk, and interventions to reduce negative long-term effects in these patients.